United States · FDA National Drug Code directory
ELAHERE
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 72903-853_47f1c78d-c469-4cd7-926e-51ce5b2d26f5
- Product NDC
- 72903-853
- Form
- INJECTION, SOLUTION
- Composition / generic term
- MIRVETUXIMAB SORAVTANSINE
- Labeler
- ImmunoGen, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20221114
- Source listing expiry
- 20271231
Source-listed ingredients
- MIRVETUXIMAB SORAVTANSINE — 5 mg/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, SINGLE-USE in 1 CARTON (72903-853-01) / 20 mL in 1 VIAL, SINGLE-USE · 72903-853-01
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →